keyword
MENU ▼
Read by QxMD icon Read
search

Diabetic macular edema

keyword
https://www.readbyqxmd.com/read/28937826/choroidal-variations-in-diabetic-macular-edema-fluorescein-angiography-and-optical-coherence-tomography
#1
Xiangning Wang, Shuting Li, Wei Li, Yanjun Hua, Qiang Wu
PURPOSES: To (i) evaluate variations in choroidal thickness (CT) and choroidal volume (CV) in diabetic macular edema (DME), as demonstrated by fluorescein angiography (FA) and enhanced depth-imaging (EDI) optical coherence tomography (OCT) (EDI-OCT) and (ii) correlate these variations with visual acuity. METHODS: This study was a retrospective observational case series of patients with diabetic retinopathy (DR) and DME. The study groups comprised 77 DR patients (n = 87), all of whom underwent color fundus photography, FA, and OCT on the same day...
September 22, 2017: Current Eye Research
https://www.readbyqxmd.com/read/28937527/relationship-between-obstructive-sleep-apnea-and-the-presence-and-severity-of-diabetic-retinopathy
#2
Aimee C Chang, Timothy P Fox, Shutao Wang, Albert Y Wu
PURPOSE: To evaluate the relationship between obstructive sleep apnea (OSA) and the presence and severity of diabetic retinopathy (DR). METHODS: Three hundred seventeen patients with International Classification of Diseases diagnoses of both DR and OSA were evaluated retrospectively. Diabetic retinopathy severity and diabetic macular edema status were determined by diagnostic coding and medical records. Obstructive sleep apnea severity and additional sleep measures were obtained from overnight polysomnography...
September 20, 2017: Retina
https://www.readbyqxmd.com/read/28935399/optical-coherence-tomography-biomarkers-as-functional-outcome-predictors-in-diabetic-macular-edema-treated-with-dexamethasone-implant
#3
Dinah Zur, Matias Iglicki, Catharina Busch, Alessandro Invernizzi, Miriana Mariussi, Anat Loewenstein
PURPOSE: Identification and characterization of patients with diabetic macular edema (DME) are important for individualizing treatment and optimizing outcome. We investigated optical coherence tomography (OCT) biomarkers for DME treated by intravitreal dexamethasone (DEX) implant. DESIGN: Multicenter, retrospective, observational cohort study. PARTICIPANTS: A total of 299 eyes from 284 patients treated with DEX implant for DME (naïve, n = 209; refractory, n = 90)...
September 18, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28931763/reversible-retinal-vessel-closure-from-vegf-induced-leukocyte-plugging
#4
Yuanyuan Liu, Jikui Shen, Seth D Fortmann, Jiangxia Wang, Dietmar Vestweber, Peter A Campochiaro
Clinical trials in patients with macular edema due to diabetic retinopathy or retinal vein occlusion (RVO) have shown that suppression of VEGF not only improves macular edema, but also reopens closed retinal vessels, prevents progression of vessel closure, and improves retinopathy. In this study, we show the molecular basis for those clinical observations. Increased retinal levels of VEGF in mice cause plugging of retinal vessels with leukocytes, vessel closure, and hypoxia. Suppression of VEGF reduces leukocyte plugging, causing reperfusion of closed vessels...
September 21, 2017: JCI Insight
https://www.readbyqxmd.com/read/28931389/semi-automated-quantification-of-hard-exudates-in-colour-fundus-photographs-diagnosed-with-diabetic-retinopathy
#5
Abhilash Goud Marupally, Kiran Kumar Vupparaboina, Hari Kumar Peguda, Ashutosh Richhariya, Soumya Jana, Jay Chhablani
BACKGROUND: Hard exudates (HEs) are the classical sign of diabetic retinopathy (DR) which is one of the leading causes of blindness, especially in developing countries. Accordingly, disease screening involves examining HEs qualitatively using fundus camera. However, for monitoring the treatment response, quantification of HEs becomes crucial and hence clinicians now seek to measure the area of HEs in the digital colour fundus (CF) photographs. Against this backdrop, we proposed an algorithm to quantify HEs using CF images and compare with previously reported technique using ImageJ...
September 20, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28924442/laser-induced-choroidal-neovascularizations-clinical-study-of-3-cases
#6
Wipada Laovirojjanakul, Thuss Sanguansak, Yosanan Yospaiboon, Supat Sinawat, Suthasinee Sinawat
BACKGROUND: We report 3 patients with laser-induced choroidal neovascularization (CNV). METHOD: Retrospective, observational case series. Medical charts and photographs were reviewed. RESULTS: Two patients with central serous chorioretinopathy who developed iatrogenic CNV after focal laser photocoagulation were treated with intravitreal ranibizumab injections. One patient with CNV secondary to thermal laser photocoagulation for diabetic macular edema was treated with photodynamic therapy (PDT)...
May 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28914687/prevention-of-macular-edema-after-cataract-surgery
#7
Laura H P Wielders, Jan S A G Schouten, Rudy M M A Nuijts
PURPOSE OF REVIEW: Although cataract surgery can effectively restore visual function in many patients with cataract, pseudophakic cystoid macular edema (PCME) remains an important cause of suboptimal visual acuity. The present review provides an overview of the current literature on the prevention and treatment of PCME. RECENT FINDINGS: Optimal prevention of PCME starts preoperatively with a personalized risk assessment. Diabetes mellitus, retinal vein occlusion, epiretinal membrane, macular hole, and uveitis are the most important risk factors for developing cystoid macular edema after cataract surgery...
September 12, 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/28904960/mystery-of-retinal-vein-occlusion-vasoactivity-of-the-vein-and-possible-involvement-of-endothelin-1
#8
REVIEW
Teruyo Kida
Retinal vein occlusion (RVO) is a common vascular disease of retina; however, the pathomechanism leading to RVO is not yet clear. In general, increasing age, hypertension, arteriosclerosis, diabetes mellitus, dyslipidemia, cardiovascular disorder, and cerebral stroke are systemic risk factors of RVO. However, RVO often occur in the unilateral eye and sometimes develop in young subjects who have no arteriosclerosis. In addition, RVO show different variations on the degrees of severity; some RVO are resolved without any treatment and others develop vision-threatening complications such as macular edema, combined retinal artery occlusion, vitreous hemorrhage, and glaucoma...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28902336/switching-anti-vegf-drugs-in-the-treatment-of-diabetic-macular-edema
#9
Touka Banaee, Mohammed Ashraf, Felipe F Conti, Rishi P Singh
Since their introduction in the late 2000s, anti-vascular endothelial growth factor (VEGF) agents have become the first-line choice for center-involved diabetic macular edema (DME). Even with its proven effectiveness, there are still cases that do not respond satisfactorily. In those cases, a treatment option is to change to another anti-VEGF drug. In this paper, the authors review studies on switching between different anti-VEGF drugs in the treatment of persistent DME. An extensive bibliographic review was done using PubMed, Embase, and Scopus...
September 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28902334/multicenter-randomized-clinical-trial-to-assess-the-effectiveness-of-intravitreal-injections-of-bevacizumab-triamcinolone-or-their-combination-in-the-treatment-of-diabetic-macular-edema
#10
Hermelino O Neto, Caio V Regatieri, Mário J Nobrega, Cristina Muccioli, Antonio M Casella, Rafael E Andrade, Mauricio Maia, Vinicius Kniggendorf, Magno Ferreira, André C Branco, Rubens Belfort
BACKGROUND AND OBJECTIVE: To evaluate the efficacy of combined bevacizumab-triamcinolone intravitreal injection in the treatment of diabetic macular edema (DME) compared to monotherapy. PATIENTS AND METHODS: At eight clinical sites, 111 patients with DME were randomly assigned to receive an intravitreal injection of bevacizumab (Avastin; Genentech, South San Francisco, CA), triamcinolone (Ophthalmos Pharmaceutical Industry, São Paulo-SP, Brazil), or their combination...
September 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28900543/switching-to-aflibercept-in-diabetic-macular-edema-not-responding-to-ranibizumab-and-or-intravitreal-dexamethasone-implant
#11
Antoine Herbaut, Franck Fajnkuchen, Lise Qu-Knafo, Sylvia Nghiem-Buffet, Bahram Bodaghi, Audrey Giocanti-Auregan
PURPOSE: To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. METHODS: We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant intravitreal injections (IVI). The primary endpoint was the mean change in visual acuity (VA) at month 6 (M6) after switching. RESULTS: Twenty-five eyes were included...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28885255/current-and-emerging-treatment-for-diabetic-macular-edema
#12
Cindy Ung, Durga S Borkar, Lucy H Young
No abstract text is available yet for this article.
2017: International Ophthalmology Clinics
https://www.readbyqxmd.com/read/28884024/combined-phacoemulsification-and-intravitreal-dexamethasone-implant-ozurdex%C3%A2-in-diabetic-patients-with-coexisting-cataract-and-diabetic-macular-edema
#13
Claudio Furino, Francesco Boscia, Alfredo Niro, Ermete Giancipoli, Maria Oliva Grassi, Giuseppe D'amico Ricci, Francesco Blasetti, Michele Reibaldi, Giovanni Alessio
PURPOSE: To investigate the effectiveness and safety of combined phacoemulsification and dexamethasone intravitreal implant in patients with cataract and diabetic macular edema. METHODS: In this two-center, retrospective, single-group study, the charts of 16 consecutive patients who underwent combined phacoemulsification and intravitreal dexamethasone implant were retrospectively reviewed. These 16 patients, 7 men and 9 women, were observed at least 3 months of follow-up...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28881150/patterns-of-retinal-thickness-prior-to-and-following-treatment-with-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-for-diabetic-macular-edema
#14
Craig J Currie, Sarah E Holden, David R Owens
OBJECTIVES: To compare retinal thickness before and after treatment with the fluocinolone acetonide (FAc) 190 µg intravitreal implant in people with diabetic macular edema (DME) using data from the Iluvien Clinical Evidence study in the UK (ICE-UK). METHODS: For this retrospective cohort study, data on people attending any one of 13 participating ophthalmology departments and treated with FAc intravitreal implant between April 1, 2013 and April 15, 2015 were collected for 12 months prior to and at least 12 months after implantation...
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881149/evaluation-of-the-clinical-effectiveness-in-routine-practice-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-in-people-with-diabetic-macular-edema
#15
Sarah E Holden, Craig J Currie, David R Owens
OBJECTIVE: The aim of the Iluvien Clinical Evidence study in the UK (ICE-UK) was to assess the real-world effectiveness of fluocinolone acetonide (FAc) 190 µg intravitreal implant for the treatment of clinically significant chronic diabetic macular edema (DME) in routine clinical practice. METHODS: This retrospective study collected data from patient medical records in 13 ophthalmology centers for people with DME prescribed FAc intravitreal implant between April 1, 2013 and April 15, 2015...
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881146/health-economic-evaluation-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-implant-in-people-with-diabetic-macular-edema
#16
Sarah E Holden, Craig J Currie, David R Owens
OBJECTIVES: To assess healthcare resource use and costs of treating people with clinically significant diabetic macular edema (DME) with fluocinolone acetonide (FAc) 190 µg intravitreal implant in routine clinical practice. METHODS: The retrospective Iluvien Clinical Evidence (ICE-UK) study collected data on people prescribed the FAc implant in any one of 13 ophthalmology centers between April 1, 2013 and April 15, 2015. Data were collected for 12 months before and after implantation...
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881143/evaluation-of-the-clinical-effectiveness-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-in-diabetic-macular-edema-a-comparison-between-study-and-fellow-eyes
#17
Craig J Currie, Sarah E Holden, Ellen Berni, David R Owens
OBJECTIVES: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetonide (FAc) 190 µg intravitreal implant for clinically significant chronic diabetic macular edema (DME) and fellow eyes not treated with FAc implant using data from the Iluvien Clinical Evidence study in the UK (ICE-UK) study. METHODS: In this retrospective cohort study, data on people attending hospital eye services and treated with the FAc implant between April 1, 2013 and April 15, 2015 were collected...
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28860707/widening-use-of-dexamethasone-implant-for-the-treatment-of-macular-edema
#18
REVIEW
Vincenza Bonfiglio, Michele Reibaldi, Matteo Fallico, Andrea Russo, Alessandra Pizzo, Stefano Fichera, Carlo Rapisarda, Iacopo Macchi, Teresio Avitabile, Antonio Longo
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of efficacy between injections with a good safety profile. Various other ocular pathologies with inflammatory etiopathogeneses associated with macular edema have been treated by DEX implant, including neovascular age-related macular degeneration, Irvine-Gass syndrome, vasoproliferative retinal tumors, retinal telangiectasia, Coats' disease, radiation maculopathy, retinitis pigmentosa, and macular edema secondary to scleral buckling and pars plana vitrectomy...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28856040/relaynet-retinal-layer-and-fluid-segmentation-of-macular-optical-coherence-tomography-using-fully-convolutional-networks
#19
Abhijit Guha Roy, Sailesh Conjeti, Sri Phani Krishna Karri, Debdoot Sheet, Amin Katouzian, Christian Wachinger, Nassir Navab
Optical coherence tomography (OCT) is used for non-invasive diagnosis of diabetic macular edema assessing the retinal layers. In this paper, we propose a new fully convolutional deep architecture, termed ReLayNet, for end-to-end segmentation of retinal layers and fluid masses in eye OCT scans. ReLayNet uses a contracting path of convolutional blocks (encoders) to learn a hierarchy of contextual features, followed by an expansive path of convolutional blocks (decoders) for semantic segmentation. ReLayNet is trained to optimize a joint loss function comprising of weighted logistic regression and Dice overlap loss...
August 1, 2017: Biomedical Optics Express
https://www.readbyqxmd.com/read/28841827/comparison-of-12-month-therapeutic-effect-of-conbercept-and-ranibizumab-for-diabetic-macular-edema-a-real-life-clinical-practice-study
#20
Yule Xu, Ao Rong, Wei Xu, Yunli Niu, Zhen Wang
BACKGROUND: To compare the efficacy of intravitreal conbercept and ranibizumab in the treatment of diabetic macular edema (DME) in a real-life clinical practice. METHODS: This was a retrospective study. Among 62 Chinese patients with DME, 32 patients (36 eyes) received intravitreal conbercept (IVC) injections and 30 patients (32 eyes) received intravitreal ranibizumab (IVR) injections, once a month for 3 months followed by as needed therapy. All participants had at least 12 months of follow-up...
August 25, 2017: BMC Ophthalmology
keyword
keyword
8162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"